
Today’s post is a round-up of recent eSubmission-related news from the agencies, based on posts from my twitter account, www.twitter.com/kathie_clark. Next time, a roundup of articles and conferences.
The regulatory authorities haven’t put out much in the way of major updates recently, but there have been some updates worth noting:
The individual agencies in Europe have also issued some updates:
As I discussed in my previous post, FDA issued version 1.5.1 of Study Data Specifications in January of 2010. Although the changes in the new version were not great, they were significant for eCTD as a new specification for organizing datasets was defined. The change has to do with how the files are organized in the file structure in which an eCTD is delivered to indicate whether they were STDM or legacy format. However, the change had no effect on the Table of Contents that is visible to a reviewer (created from the eCTD XML backbone). In a recent development, ICH M2 working group has defined an update to the valid values list for study tagging files to introduce file tags that would allow a review tool to identify dataset types when displaying the eCTD Table of Contents.
The new specifications for organizing study datasets and their associated files in folders are summarized in the following figure. In the document, an accompanying table provides further definition of the folders.
New Dataset Folder Organization
Compare this with the folder structure required in the previous specification:
Previous Dataset Folder Organization
You will see an important difference: tabulations must be assigned to a folder based on whether they are STDM datasets or legacy format. A second difference is that there is now a separate folder for datasets under analysis, where previously analysis datasets were placed directly in the analysis folder.
At the recent ICH meeting in Estonia, the valid-values.xml that defines file tags used to identify the documents in studies was amended to better support the different types of data:
Look for the new valid-values.xml on the ICH websites in a zip file. You should talk with your publishing vendor to find out how and when they will support the updated specification.
One final note – the FDA recently retired their own version of the valid-values.xml and reverted to the ICH version. That means that they restored the file tag of nonclinical-data. However, the preferred file tag for a nonclinical study is pre-clinical-study-report.
The ICH M2 ESTRI Main Page has been updated with the following announcement:
“ICH M2 has initiated the development of the Next Major Version of the eCTD (eCTD NMV) to improve robustness, flexibility and long term stability of the message. In accordance with the decision by the ICH Steering Committee that technical specifications should no longer be developed solely within ICH, but should be created in collaboration with Standards Development Organisations (SDOs), the eCTD NMV will be developed jointly with the HL7 RPS project. M2 has developed this list of requirements as input into the HL7 RPS Project.”
I took a look at the requirements (which have been posted before in various drafts). They stretch to nine pages, and range from some that are uncontroversial and obvious to some that signal a significant change in direction. In this posting, I point out some of the more interesting requirements.
Regulatory Activities
The new spec really supports the concept of organizing sequences into regulatory activities. A regulatory activity is a collection of sequences that lead to a decision by the regulatory agency (such as an MAA, Variation, NDS, SNDS, Original NDA, Supplement, etc.) which can be mapped to individual ICH-regional regulatory processes. This concept does not exist in ICH eCTD, although the regional authorities have added it using the concept of “related sequence.” The NMV spec includes a number of formal requirements to support the Regulatory Activity concept.
Cross Application References
Current eCTD does not support cross application references, but neither does it prohibit their use. The only authority to my knowledge who actively supports them is the FDA (who will send you a document providing directions if you email them at esub@fda.hhs.gov ). EMEA expressly forbids them.
The new spec explicitly supports them as shown in the following requirements:
Future of Study Tagging Files (STFs)
When I first read the requirement
When the same documentation is provided, it should be submitted in the same way across HAs. For example, when a study report is submitted in US it is submitted using the STF which is not acceptable in other HAs. This minimizes reuse capabilities and adds to Industry costs to prepare globally harmonized dossiers.
I wasn’t sure if ICH was suggesting that the STF concept should go away altogether. I asked my colleague Jason Rock, who represents the FDA at ICH M2. Jason explained that the goal was to do away with the STF as a separate XML file. STF information would be contained in the main backbone, and could be ignored by authorities who don’t want it. This was also confirmed in a later requirement reading “STF construct should be integrated into the message standard.”
Maintenance of Metadata:
Many sponsors have experienced problems with their eCTD due to the inability of the standard to accommodate corrections or changes in metadata (such as manufacturer). eCTD NMV requirements include the requirement for the message to support the addition, updating and deletion of metadata to a previously submitted instances, e.g., related sequences, submission type, operation attribute, manufacturer name, etc.
Lifecycle
New NMV requirements regarding lifecycle are likely to be applauded by sponsors:
Physical File Rules
The days of relying on a standard folder structure for XML-based eSubmissions are coming to an end as all parties move to acknowledge that they should be using the backbone/TOC and not the file system. The NMV spec includes a requirement that “The physical file structure. (file/folder structure) should be minimal”.
File names would also be able to include underscores, which will come as a relief to anyone who has struggled with if or how to eliminate underscores from SAS file names.
Logical Groupings
New mechanisms for grouping files at levels below sections are called for:
Scope
An important architectural concept for eCTD NMV/RPS is the separation of the messaging mechanism from the TOC. The TOC is no longer built into the specification, but supplied by the regional authorities. This is encapsulated in the requirement “Allow the capacity to modify the ICH CTD organizational structure (ToC) without modifying or changing the eCTD message structure.”
Compatibility
For those worried about the impact of the switch on their current eCTDs, some compatibility requirements should provide some reassurance:
***This just in: our first session is completely full, and we have added a second session on December 8th, 11 am EST (a time more friendly to our European colleagues):
http://www.eventbrite.com/event/474671756
_______________________________________________________________
Don’t have time to keep up-to-date on eCTD regulations and guidance around the world? Wondering when eCTD will become mandatory, (or even accepted), in a given market? Join GlobalSubmit and Cato Research on Thursday, November 5th at 2:00 PM EST for a free educational webinar titled, eCTD Regulations and Status Worldwide.
I’ll be the main presenter, and I’ll review the status of eCTD in the US, Europe, Canada, Japan, Australia and Switzerland. I will also provide you with a convenient list of references and contacts.
At the end of the session’s Q&A, a CATO representative will give a brief overview of the latest happenings in the CRO realm and answer any questions you may have.
Date: November 5, 2009
Time: 2:00 PM EST
Please note: this event is designed for sponsors, and is open only to users registering with a valid email address from a pharmaceutical domain (no gmail, yahoo, etc. accounts).
To Register: Click here or paste this URL into your browser: http://www.eventbrite.com/event/471856335
The RPS (Regulated Product Submissions) Working Group is preparing for a September 23 working group meeting in Atlanta. Topics include:
Just a reminder that all sorts of good stuff is on the HL7 RPS Wiki!
Last week I was at the ICH meeting in Japan. If you haven’t been to Japan, I highly recommend a visit to this beautiful country and its very friendly people.
We had a productive meeting. My time was split between working on eCTD and ICSR. The eCTD group focused on change requests and requirements for the next major version. While there were no significant changes made, we are working hard to include Module 3 Q&A as soon as possible. The change request will be posted to the ICH website in the near future.
One of the things the group focused on was reviewing which PDF version can be accepted by all parties. There were no changes to the PDF 1.4 recommendation, but all parties agreed to determine the feasibility of endorsing the ISO32000 PDF version soon. That said, it’s a very real possibility that ISO32000 PDF will be endorsed at the October 2009 meeting. We are also looking at using XML as a replacement for PDF. Do not expect that change any time soon.
The group also made tremendous progress in determining ICH requirements for the next major version of eCTD. Since we did not complete said requirements however, I would fully expect that ICH will officially participate in the RPS standard after the October 2009 meeting.
In the margins of the meeting – meaning at the hotel bar –differences between US and European submission were discussed. I learned, for instance, that original marketing applications in the US are typically five to 10 times larger in page count and file size than European submissions. I also found out that there is a 10+ multiple in the number of amendments found in the average US submissions when compared to a similar European submission. In fact, one sponsor said that a drug approved in Europe had four sequences, while the same drug in the US had 78 sequences. Now that’s something to think about.
This is not really new news, but ICH has posted the short presentation ”Update on the eCTD“ from the November meeting on their website. This presentation was given by Joe Cipollina.
The key elements of the presentation include:
The ICH M2 Group focus will be to:
So it’s official, folks - RPS is coming!
It’s time to get educated. In a previous post, I mentioned the RPS wiki and list server.
Also, keep your eyes on my company’s web site www.globalsubmit.com. My colleague Jason Rock, who serves on the leadership steering team that is developing RPS, will be presenting a series of RPS educational sessions at the request of the FDA. You will be able to register for these sessions on our website shortly.
In general, the changes proposed in Version 3.3.3 were more beneficial to industry that to regulators. The agencies had concerns about the cost and effort of implementing the specification as it was largely focused on incorporating the STF into the eCTD backbone. FDA already considers that they have a satisfactory solution in the STF as it stands, and other regions have not identified any requirements for the STF. Japan in particular was said to be concerned about having to update newly completed procedures and tools to support 3.3.3 in the short term; however, a PMDA representive at the DIA Doc Management meeting expressed “strong support” for eCTD 4.0 during the February 7th International Regulatory Update session.
The M2 EWG also expressed a desire to improve the narrative portion of the specification and address those change requests that can be resolved without changes to the DTD. To the extent possible, existing Q&As will also be incorporated. This revised specification document will be issued as eCTD Version 3.2.1 during the coming months. Version 3.2.1 of the eCTD specification will be accompanied by an updated version of the Study Tagging File (STF) specification, version 2.6.1, which will address improvements to the narrative portion of this specification in the same way but will also not make any changes to the existing STF DTD.
See http://estri.ich.org/eCTD/news.htm for details.